Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Endocrinology

Signs, Symptoms, and the Road to Diagnosis

At a Glance

AKT2-related familial partial lipodystrophy often causes fat loss in the arms and legs with fat accumulation elsewhere, severe insulin resistance, and related metabolic problems. Diagnosis combines physical findings, metabolic clues, body-fat imaging, and genetic testing.

Familial Partial Lipodystrophy (FPLD) is not a condition of weight, but of weight distribution. Because your body cannot store fat in the normal “warehouses” under the skin of your arms and legs, it is forced to store that energy elsewhere [1][2].

(Note: The following physical signs primarily apply to patients with loss-of-function AKT2 variants that cause lipodystrophy. Those with activating variants causing hypoglycemia may not experience these changes.)

The physical hallmarks of FPLD often become visible around puberty and include:

  • Lipoatrophy (Fat Loss): A selective loss of fat from the legs, hips, and arms. This can make your limbs appear very thin or intensely muscular, as there is no layer of fat to soften the appearance of the muscles [1][3].
  • Prominent Veins: Because the subcutaneous fat is missing, veins in the arms and legs may appear unusually visible or “bulging” (phlebomegaly) [4][3].
  • Adipose Accumulation: Fat that cannot go to the limbs may accumulate in the face, neck, and upper back (sometimes called a “buffalo hump”), or deep inside the abdomen around the organs (visceral fat) [2][1].
  • Acanthosis Nigricans: Dark, velvety patches of skin, typically in the armpits or around the neck, which are a physical sign of severe insulin resistance [5][6].

How Doctors Diagnose FPLD

A diagnosis usually begins with a clinical suspicion framework. In many expert guidelines, a clinician might suspect FPLD if there is lower-limb lipoatrophy (noticeable fat loss in the legs) plus at least one of the following metabolic clues [7]:

  1. Severe Hypertriglyceridemia: Very high levels of fat (triglycerides) in the blood [7][8].
  2. Early-Onset Diabetes: High blood sugar that often requires unusually high doses of insulin to manage [2][9].
  3. Metabolic Liver Disease: Fat accumulation in the liver (steatosis) [7][6].
  4. Reproductive Signs: In women, this often presents as Polycystic Ovary Syndrome (PCOS) features, such as irregular periods or excess hair growth (hirsutism) [7][10].

Tools Used to Support the Diagnosis

While a physical exam is the most important tool, your care team may use objective tests to map your body fat. It is important to note that there is no single numerical cutoff that confirms disease; these are interpreted by your clinician as part of a larger picture:

  • Skinfold Measurements: A technician uses calipers to measure the thickness of fat at specific points. Very low thigh or calf skinfolds can support a diagnosis of FPLD, though measurements vary by age, sex, and technician [11][12].
  • DXA Scan: Similar to a bone density scan, a DXA can calculate your trunk-to-leg fat ratio. In FPLD, this ratio is typically much higher than normal because the legs are depleted of fat while the trunk is not [13][14].
  • Whole-Body MRI: This provides a detailed map of exactly where fat is stored (and where it is missing), helping to distinguish FPLD from other conditions [14][15].
  • Genetic Testing: Finding a pathogenic variant in the AKT2 gene supports the diagnosis and helps predict your specific metabolic risks [5][2]. However, this must always be matched with your physical symptoms.

Why Misdiagnosis is Common

Because FPLD is so rare, it is frequently mistaken for more common conditions. You may have been treated for years for one of the following before receiving your AKT2 diagnosis:

  • Type 2 Diabetes: Doctors may assume a patient has “standard” Type 2 diabetes, but they may be puzzled by how thin the patient’s legs are or how much insulin they require [6][9].
  • Polycystic Ovary Syndrome (PCOS): The severe insulin resistance in FPLD often causes the same hormonal imbalances as PCOS. If a patient has PCOS symptoms plus very high triglycerides or thin limbs, FPLD should be considered [10][16].
  • Cushing Syndrome: Because both conditions can cause fat accumulation in the face and neck while the limbs remain thin, they can look remarkably similar. However, the cause of the fat distribution is entirely different [1][4].
  • Anorexia Nervosa: In some cases, the extreme lack of visible fat on the limbs can lead to a misdiagnosis of an eating disorder, even though the patient is eating normally [17][6].

Understanding that your symptoms are caused by a genetic “wiring” issue in the AKT2 gene—rather than lifestyle or a common hormonal disorder—is the first step toward a more targeted and effective treatment plan.

Common questions in this guide

What physical changes can suggest AKT2-related familial partial lipodystrophy?
AKT2-related familial partial lipodystrophy often causes fat loss in the arms, legs, and hips, making the limbs look unusually thin or muscular and making veins more visible. Fat may build up in the face, neck, upper back, or abdomen, and dark, velvety skin patches can signal severe insulin resistance.
How do doctors test for AKT2-related familial partial lipodystrophy?
Doctors start with a physical examination and look for regional fat loss plus clues such as very high triglycerides, early diabetes, fatty liver, or polycystic ovary syndrome features. Skinfold measurements, a DXA scan, whole-body MRI, metabolic tests, and AKT2 genetic testing may add evidence, but no single measurement or test confirms the diagnosis by itself.
What can a DXA scan show if FPLD is suspected?
A DXA scan estimates how much fat is stored in different parts of the body and can calculate the trunk-to-leg fat ratio. In FPLD, the ratio may be high because the legs have less fat, but the result must be interpreted with the examination and other findings.
Why might FPLD be mistaken for type 2 diabetes or PCOS?
Severe insulin resistance can cause high blood sugar, a need for unusually large insulin doses, irregular periods, and excess hair growth, which can resemble type 2 diabetes or PCOS. Thin or muscular-looking limbs, very high triglycerides, or fatty liver can point to an underlying fat-distribution disorder instead.
What does a pathogenic AKT2 variant mean for diagnosis?
A disease-causing change in the AKT2 gene supports AKT2-related familial partial lipodystrophy and may help identify metabolic risks. Genetic results still need to match the person's physical findings and medical history, because different AKT2 changes can have different effects, including low blood sugar rather than the same fat-loss pattern.
Should someone with suspected FPLD be checked for fatty liver?
A clinician may recommend checking the liver because fat can accumulate there in FPLD. Depending on the person's findings, evaluation may include an ultrasound or transient elastography, also called a FibroScan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my physical exam, which specific 'depots' or areas of fat are considered abnormally low or high for my age?
  2. 2.Can we perform skinfold measurements or a DXA scan to objectively calculate my trunk-to-leg fat ratio?
  3. 3.Does my genetic variant (AKT2) explain my symptoms better than a diagnosis of PCOS or metabolic syndrome?
  4. 4.Should we screen for fatty liver using an ultrasound or transient elastography (FibroScan)?
  5. 5.If my fat loss is 'regional' rather than 'partial,' does that change how you monitor my heart and liver health?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review.

    Fernandez-Pombo A, Diaz-Lopez EJ, Castro AI, et al.

    Cells 2023; (12(5)) doi:10.3390/cells12050725.

    PMID: 36899861
  2. 2

    Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).

    Mosbah H, Donadille B, Vatier C, et al.

    Orphanet journal of rare diseases 2022; (17(Suppl 1)):170 doi:10.1186/s13023-022-02308-7.

    PMID: 35440056
  3. 3

    Fitting the pieces of the puzzle together: a case report of the Dunnigan-type of familial partial lipodystrophy in the adolescent girl.

    Krawiec P, Mełges B, Pac-Kożuchowska E, et al.

    BMC pediatrics 2016; (16()):38 doi:10.1186/s12887-016-0581-2.

    PMID: 26976018
  4. 4

    An adolescent girl referred with Cushing syndrome--does she or does she not have the syndrome?

    Kao KT, Zacharin M

    Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(1)):109-12.

    PMID: 26677885
  5. 5

    Lipodystrophy for the Diabetologist-What to Look For.

    Patni N, Garg A

    Current diabetes reports 2022; (22(9)):461-470 doi:10.1007/s11892-022-01485-w.

    PMID: 35821558
  6. 6

    Primary disease of adipose tissue: When to think about and how to evaluate it in clinical practice?

    Vatier C, Vigouroux C, Mosbah H

    Annales d'endocrinologie 2024; (85(3)):190-194 doi:10.1016/j.ando.2024.05.019.

    PMID: 38871502
  7. 7

    Brazilian expert consensus on the diagnosis, classification, screening for complications and treatment of familial partial lipodystrophy.

    Valerio CM, Viola LF, Guidorizzi NR, et al.

    Diabetology & metabolic syndrome 2025; (17(1)):186 doi:10.1186/s13098-025-01733-5.

    PMID: 40452043
  8. 8

    Phenotypic Differences Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants.

    Vasandani C, Li X, Sekizkardes H, et al.

    Journal of the Endocrine Society 2022; (6(12)):bvac155 doi:10.1210/jendso/bvac155.

    PMID: 36397776
  9. 9

    Coincidence of Autoimmune Diabetes Mellitus and Familial Partial Lipodystrophy.

    Krienke M, Schmidt HHJ, Buettner J, et al.

    JCEM case reports 2025; (3(12)):luaf265 doi:10.1210/jcemcr/luaf265.

    PMID: 41221014
  10. 10

    Familial partial lipodystrophy as differential diagnosis of polycystic ovary syndrome.

    Lewandowski KC, Lewiński A, Dąbrowska K, et al.

    Endokrynologia Polska 2015; (66(6)):550-4 doi:10.5603/EP.2015.0067.

    PMID: 26662654
  11. 11

    Calf skinfold measurements as a diagnostic tool for lipodystrophy syndromes: a cross-sectional study.

    da Cruz Paiva Lima GE, de Moura Lopes FK, Araújo JS, et al.

    Diabetology & metabolic syndrome 2025; (17(1)):388 doi:10.1186/s13098-025-01934-y.

    PMID: 41074178
  12. 12

    Anthropometric measurements as a key diagnostic tool for familial partial lipodystrophy in women.

    Veras VR, da Cruz Paiva Lima GE, da Ponte Melo I, et al.

    Diabetology & metabolic syndrome 2024; (16(1)):216 doi:10.1186/s13098-024-01413-w.

    PMID: 39227868
  13. 13

    Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety.

    Vasandani C, Li X, Sekizkardes H, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(7)) doi:10.1210/clinem/dgaa137.

    PMID: 32193531
  14. 14

    Clinical and imaging features of women with polygenic partial lipodystrophy: a case series.

    Loh WJ, Yaligar J, Hooper AJ, et al.

    Nutrition & diabetes 2024; (14(1)):3 doi:10.1038/s41387-024-00260-y.

    PMID: 38321009
  15. 15

    Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy.

    Altay C, Seçil M, Demir T, et al.

    Diagnostic and interventional radiology (Ankara, Turkey) 2017; (23(6)):428-434 doi:10.5152/dir.2017.17019.

    PMID: 29044029
  16. 16

    Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.

    Resende ATP, Martins CS, Bueno AC, et al.

    Clinical endocrinology 2019; (91(1)):94-103 doi:10.1111/cen.13984.

    PMID: 30954027
  17. 17

    Serum levels of adiponectin differentiate generalized lipodystrophies from anorexia nervosa.

    Ceccarini G, Pelosini C, Paoli M, et al.

    Journal of endocrinological investigation 2024; (47(8)):1881-1886 doi:10.1007/s40618-024-02308-3.

    PMID: 38358463

This page is for informational purposes only and does not constitute medical advice. An endocrinology or genetics professional should interpret your symptoms, imaging, laboratory results, and AKT2 test in context.

Get notified when new evidence is published on AKT2-related familial partial lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.